IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion

Journal of Clinical Investigation

Volumn 105, Issue 12, 2000, Pages 1697-1710

  Lubberts, Erik ^a   Joosten, Leo A B ^a   Chabaud, Martine ^b   Van Den Bersselaar, Liduine ^a   Oppers, Birgitte ^a   Coenen De Roo, Christina J J ^c   Richards, Carl D ^d   Miossec, Pierre ^b   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c NV ORGANON   (Netherlands)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; CATHEPSIN K; COLLAGEN TYPE 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PROCOLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; BONE STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE THERAPY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TISSUE REPAIR;

EID: 0033933776     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7739     Document Type: Article

References (69)

1. Nijweide, P.J., Burger, E.H., and Feyen, J.H.M. 1986. Cells of the bone: proliferation, differentiation, and hormonal regulation. Physiol. Rev. 66:855-886.
2. Manolagas, S.C., and Jilka, R.L. 1995. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-311.
3. Roodman, G.D. 1996. Advances in bone biology: the osteoclast. Endocr. Rev. 17:308-332.
4. Suda, T., Takahashi, N., and Martin, T.J. 1992. Modulation of osteoclast differentiation. Endocr. Rev. 13:66-80.
5. Firestein, G.S., Alvaro Garcia, J.M., and Maki, R. 1990. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144:3347-3353.
6. Chen, E., Keystone, E.C., and Fish, E.N. 1993. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum. 36:901-910.
7. Bromley, M., and Wooley, D.E. 1984. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27:968-975.
8. Leisen, J.C.C., Duncan, H., Riddle, J.M., and Richford, W.C. 1988. The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J. Rheumatol. 15:17-22.
9. Gravallese, E.M., et al. 1998. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152:943-951.
10. Suzuki, Y., Nishikaku, F., Nakatuka, M., and Koga, Y. 1998. Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 25:1154-1160.
11. Arend, W.P., and Dayer, J.-M. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38:151-160.
12. Feldmann, M., Elliot, M.J., Woody, J.N., and Maini, R.N. 1997. Antitumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv. Immunol. 64:282-350.
13. Müller-Ladner, U., Gay, R.E., and Gay, S. 1998. Molecular biology of cartilage and bone destruction. Curr. Opin. Rheumatol. 10:212-219.
14. Pfeilschiffer, J., Chenu, C., Bird, A., Mundy, G.R., and Roodman, G.D. 1989. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J. Bone Miner. Res. 4:113-118.
15. Lowik, C.W., et al. 1989. Parathyroid hormone and PTH-like protein stimulated interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:546-552.
16. Ishimi, Y., et al. 1990. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 146:3297-3303.
17. De la Mata, J., et al. 1995. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo J. Clin. Invest. 95:2846-2852.
18. O'Keefe, R.J., et al. 1997. Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study. Lab. Invest. 76:457-465.
19. Kotake, S., et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352.
20. Chabaud, M., et al. 1999. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42:963-970.
21. Kong, Y.-Y., et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315-323.
22. Chomarat, P., and Banchereau, J. 1997. An update on interleukin-4 and its receptor. Eur. Cytokine Netw. 8:333-344.
23. Moore, K.W., O'Garra, A., De Waal-Malefyt, R., Vieira, P., and Mosmann, T.R. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190.
24. Joosten, L.A.B., et al. 1997. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum. 40:249-260.
25. Lubberts, E., Joosten, L.A.B., Helsen, M.M.A., and Van den Berg, W.B. 1998. Regulatory role of interleukin-10 in joint inflammation and cartilage destruction in murine streptococcal cell wall arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine. 10:361-369.
26. Lubberts, E., et al. 1999. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J. Immunol. 163:4546-4556.
27. Miossec, P., and Van den Berg, W.B. 1997. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 40:2105-2115.
28. Watanabe, K., et al. 1990. Interleukin-4 as a potent inhibitor of bone resorption. Biochem. Biophys. Res. Commun. 172:1035-1041.
29. Bizzarri, C., et al. 1994. Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts. J. Biol. Chem. 269:13817-13824.
30. Miossec, P., et al. 1994. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum. 37:1715-1722.
31. Onoe, Y., et al. 1996. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblast. J. Immunol. 156:758-764.
32. Riancho, J.A., Zarrabeitia, M.T., Mundy, G.R., Yoneda, T., and Gonzales-Macias, J. 1993. Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. J. Bone Miner. Res. 8:1337-1344.
33. Kasono, K., et al. 1993. Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture. Bone Miner. 21:179-188.
34. Trentham, D.E., Townes, A.S., and Kang, A.H. 1977. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 146:857-868.
35. Courtenay, J.S., Dallman, M.J., Dayan, A.B., Martin, A., and Mosedale, B. 1980. Immunization against heterologous type II collagen-induced arthritis in mice. Nature. 283:666-668.
36. Stuart, J.M., Townes, A.S., and Kang, A.H. 1982. Nature and specificity of immune responses to collagen in type II collagen-induced arthritis in mice. J. Clin. Invest. 69:673-683.
37. Hogaboam, C.M., et al. 1997. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J. Clin. Invest. 100:2766-2776.
38. Xing, Z., Ohkawara, Y., Jordana, M., Graham, F.L., and Gauldie, J. 1996. Transfer of GM-CSF gene to rat lung induces eosinophilia, monocytosis and fibrotic reactions. J. Clin. Invest. 97:1102-1110.
39. Van Meurs, J.B.J., Van Lent, P.L.E.M., Joosten, L.A.B., Van der Kraan, P.M., and Van den Berg, W.B. 1997. Quantification of mRNA levels in joint capsule and articular cartilage of the murine knee joint by RT-PCR. Rheumatol. Int. 16:197-205.
40. Chomczynski, P., and Sacchi, N. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
41. Van den Berg, W.B., Joosten, L.A.B., and Van de Putte, L.B.A. 1984. Electrical charge of the antigen determines intraarticular handling and chronicity of arthritis in mice. J. Clin. Invest. 74:1850-1859.
42. Billinghurst, R.C., et al. 1997. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99:1534-1545.
43. Aimes, R.T., and Quigley, J.P. 1995. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 1/4- and 3/4-length fragments. J. Biol. Chem. 270:5872-5876.
44. Arnett, F.C., et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324.
45. Bonde, M., et al. 1997. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 12:1028-1034.
46. Garnero, P., Sornay-Rendu, E., Chapuy, M.C., and Delmas, P.D. 1996. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11:337-349.
47. Kikuchi, K., et al. 1995. Elevated procollagen type I carboxyterminal propeptide production in cultured scleroderma fibroblasts. Dermatology. 190:104-108.
48. Lubberts, E., et al. 2000. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin. Exp. Immunol. 120:375-383.
49. Kong, Y.-Y., et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:304-309.
50. Hummel, K.L., et al. 1998. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J. Rheumatol. 25:1887-1894.
51. Joosten, L.A.B., Helsen, M.M.A., Van de Loo, F.A.J., and Van den Berg, W.B. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum. 39:797-809.
52. Van den Berg, W.B., Joosten, L.A.B., Helsen, M.M.A., and Van de Loo, A.J.J. 1994. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 11:237-243.
53. Bakker, A.C., et al. 1997. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 40:893-900.
54. Van de Loo, F.A.J., Joosten, L.A.B., Van Lent, P.L.E.M., Arntz, O.J., and Van den Berg, W.B. 1995. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38:164-172.
55. Van Meurs, J.B.J., et al. 1998. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis Rheum. 41:647-656.
56. Ghivizzani, S.C., et al. 1998. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad. Sci. USA. 95:4613-4618.
57. Guerne, P.A., Zuraw, B.L., Vaughan, J.H., Carson, D.A., and Lotz, M. 1989. Synovium as a source of interleukin-6 in vitro: contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83:585-592.
58. Miossec, P., et al. 1992. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum. 35:874-883.
59. Jilka, R.L., et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:88-91.
60. Takayanagi, H., et al. 1997. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblast induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240:279-286.
61. Pesanti, E.L., and Lorenzo, J.A. 1998. Osteoclasts and effects of interleukin-4 in development of chronic osteomyelitis. Clin. Orthop. 355:290-299.
62. Tezuka, K., et al. 1994. Molecular cloning of a possible cystein proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 269:1106-1109.
63. Drake, F.H., et al. 1996. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271:12511-12516.
64. Osada, K., et al. 1994. Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis. Br. J. Dermatol. 131:655-659.
65. Hakala, M., Risteli, L., Manelius, J., Nieminen, P., and Risteli, J. 1993. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 52:866-869.
66. Kotaniemi, A., Isomaki, H., Hakala, M., Risteli, L., and Risteli, J. 1994. Increased type I collagen degradation in early rheumatoid arthritis. J. Rheumatol. 21:1593-1596.
67. Garnero, P., Jouvenne, P., Buchs, N., Delmas, P.D., and Miossec, P. 1999. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone. 24:381-385.
68. Van den Berg, W.B. 1998. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin. Immunopathol. 20:149-164.
69. Bresnihan, B., et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196-2204.